Biotech layoffs slow as companies like BioNTech cut nearly 1,900 jobs amid market pressures

The biotech sector has seen more than 40 layoff announcements through the end of April 2026, a decline from the over 50 rounds reported in the final months of 2025. Analysts had expected the pace to ease early in the year, and the data now suggests a modest reduction in job cuts.

Market turbulence in the United States, including tariff threats, proposals for most‑favored‑nation pricing, and ongoing cost pressures from the Inflation Reduction Act, contributed to a 16% rise in layoffs year‑over‑year last year. This volatility has tempered optimism about a smoother hiring environment.

Companies are attributing the current reductions to a mix of investigational drug failures, strategic reprioritizations, and efforts to improve operational efficiency. These factors are driving both planned and unplanned workforce adjustments across the industry.

BioNTech announced a major restructuring in early May, shifting focus toward oncology and scaling back its COVID‑19 vaccine manufacturing in Germany and Singapore, which will eliminate roughly 1,860 positions. Other firms, such as Vistagen, are also trimming staff, targeting about a 20% reduction to conserve cash and concentrate on lead candidates.